BCL-XL - a biomarker to predict chronic myeloid leukaemia patients at risk of molecular relapse when TKI treatment is discontinued

被引：0
|
作者：
Lucas, C. [1 ,2 ]
Austin, G. [1 ]
Holcroft, A. [1 ]
Knight, K. [2 ]
Varadarjan, S. [1 ]
Clark, R. [1 ,2 ]
机构：
[1] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
BCLXL; CML; Remission; Treatment perspectives;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：55 / 55
页数：1
相关论文
共 50 条
  • [1] Differences in BCL-XL expression and STAT5 phosphorylation in chronic myeloid leukaemia patients
    Gutiérrez-Castellanos, S
    Cruz, M
    Rabelo, L
    Godínez, R
    Reyes-Maldonado, E
    Riebeling-Navarro, C
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2004, 72 (04) : 231 - 238
  • [2] Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia
    方亚
    Alois Gratwohl
    Hans C.van Houwelingen
    中华医学杂志(英文版), 2003, (02) : 145 - 148
  • [3] Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia
    方亚
    Alois Gratwohl
    Hans C.van Houwelingen
    ChineseMedicalJournal, 2003, (02)
  • [4] Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia
    Fang, Y
    Gratwohl, A
    Van Houwelingen, HC
    CHINESE MEDICAL JOURNAL, 2003, 116 (02) : 305 - 308
  • [5] USING BIOMARKER CHANGE AND TREATMENT ADHERENCE TO PREDICT RISK OF RELAPSE AMONG CHRONIC MYELOID LEUKEMIA PATIENTS WHO ARE IN REMISSION
    Montano-Campos, J. F.
    Haupt, E. C.
    Hahn, E. E.
    Radich, J.
    Bansal, A.
    VALUE IN HEALTH, 2023, 26 (06) : S11 - S11
  • [6] The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients
    Kurtovic-Kozaric, Amina
    Hasic, Azra
    Radich, Jerald P.
    Bijedic, Vildan
    Nefic, Hilada
    Eminovic, Izet
    Kurtovic, Sabira
    Colakovic, Ferida
    Kozaric, Mirza
    Vranic, Semir
    Bovan, Nada S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (03) : 420 - 427
  • [7] TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia
    Claudiani, Simone
    Apperley, Jane F.
    Szydlo, Richard
    Khan, Afzal
    Nesr, George
    Hayden, Chloe
    J. Innes, Andrew
    Dominy, Kathy
    Foskett, Pierre
    Foroni, Letizia
    Khorashad, Jamshid
    Milojkovic, Dragana
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 (02) : 346 - 355
  • [8] Balancing Benefits and Risk During Treatment of Paediatric Patients (pts) with Chronic Myeloid Leukaemia (CML) by Tyrosine Kinase Inhibitors (TKI)
    Suttorp, M.
    Tauer, J. T.
    Jaeger, B. A. S.
    Rosen-Wolff, A.
    KLINISCHE PADIATRIE, 2011, 223 (01): : 46 - 46
  • [9] Whole-exome sequencing for relapse prediction in patients discontinuing TKI treatment in chronic myeloid leukemia
    Abedin, Sameem
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1503 - 1504
  • [10] The Depth Of 'Complete' Molecular Response Predicts Molecular Relapse In Chronic Myeloid Leukaemia Patients On Tyrosine Kinase Inhibitor Therapy
    Thomas, Heledd
    Apperley, Jane F.
    Szydlo, Richard M.
    Gerrard, Gareth
    Marin, David
    Milojkovic, Dragana
    Foroni, Letizia
    BLOOD, 2013, 122 (21)
12345